Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041962 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Takao Susa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Teikyo University School of Medicine, Tokyo 173-8605, Japan. Hauptthemen laut MEDLINE: Homeodomain Proteins, Receptors, Androgen, Prostatic Neoplasms, Signal Transduction. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Because prostate cancer proliferates in an androgen-dependent manner, various inhibitors of androgen production and antagonists of the androgen receptor (AR) are used as therapeutic agents. However, the emergence of castration-resistant prostate cancer has prompted the development of additional treatment strategies. In this study, we focused on the antiprostate cancer effects of vitamin D3 and examined novel antiproliferative effects through the crosstalk with androgen signaling. In human prostate cancer LNCaP cells, homeobox C9 (HOXC9) was identified as a common regulated target gene by dihydroxytestosterone and 1α,25-dihydroxyvitamin D3, but in opposite directions. Ligand-stimulated AR and vitamin D receptor competitively shared binding sites in the HOXC9 regulatory region, but dihydroxytestosterone stimulation preferentially suppressed HOXC9 expression due to the stronger binding properties of AR and the induction of DNA methylation. Forced expression of HOXC9 inhibited androgen signaling to eliminate the androgen-dependent proliferation by associating with the AR transcription complex, in part due to interference with AR binding to some of its targets in LNCaP cells. In summary, this study provides evidence for the involvement of HOXC9 in antiproliferative effects through a regulatory mechanism mediated by a crosstalk between vitamin D receptor and AR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
- Department of Internal Medicine, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
- Medical Education Center, Teikyo University School of Medicine, Tokyo 173-8605, Japan.
ORCID-Profile: Takao Susa, Miho Akimoto, Masayoshi Iizuka
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Susa, T., Tsuboi, E., Okada, T., Akimoto, M., Okudaira, N., Okinaga, H., Iizuka, M., Okazaki, T., & Tamamori-Adachi, M. (2026). Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041962
Vancouver
Susa T, Tsuboi E, Okada T, Akimoto M, Okudaira N, Okinaga H, et al. Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041962
BibTeX
@article{Susa2026,
author = {Susa, Takao and Tsuboi, Eiki and Okada, Tomoko and Akimoto, Miho and Okudaira, Noriyuki and Okinaga, Hiroko and Iizuka, Masayoshi and Okazaki, Tomoki and Tamamori-Adachi, Mimi},
title = {Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041962}
}
EUVIMED